Last reviewed · How we verify
NCT04714515
Montelukast - a Treatment Choice for COVID-19
trial testing Montelukast in Covid19 in 150 participants. Completed in 20 April 2020.
30 March 2020
Quick facts
| Lead sponsor | University of Sargodha |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 20 February 2020 |
| Primary completion | 30 March 2020 |
| Estimated completion | 20 April 2020 |
| Sites | 2 locations across China, Pakistan |
Drugs / interventions tested
- Montelukast (montelukast) — full drug profile →
- Hydroxychloroquine (HYDROXYCHLOROQUINE) — full drug profile →
- Ivermectin (ivermectin) — full drug profile →
Conditions studied
- Covid19 — all drugs for Covid19 →
- SARS-CoV-2 Infection — all drugs for SARS-CoV-2 Infection →
Sponsor
University of Sargodha
Who can join
Adults 20 to 80, any sex, with Covid19 or SARS-CoV-2 Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The current study aimed to make a therapeutic comparison and effectiveness of Hydroxychloroquine (HCQ) and Montelukast (ML) in COVID-19 patients in addition to the standard of care. The safety and efficacy of HCQ and ML will be assessed as individual therapy and in combination with each other and with the standard of care. Cytokine storm (Interleukin levels) also will be monitored throughout the study to assess treatment progression.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.
Hu S, Jiang S, Qi X, Bai R, et al · · 2022 · cited 68× · PMID 34762760 · DOI 10.1002/ddr.21895 -
The roles of lipids in SARS-CoV-2 viral replication and the host immune response.
Theken KN, Tang SY, Sengupta S, FitzGerald GA. · · 2021 · cited 59× · PMID 34599996 · DOI 10.1016/j.jlr.2021.100129 -
Cytokine Storm Syndrome in SARS-CoV-2 Infections: A Functional Role of Mast Cells.
Hafezi B, Chan L, Knapp JP, Karimi N, et al · · 2021 · cited 41× · PMID 34359931 · DOI 10.3390/cells10071761 -
TEG<sup>®</sup>, Microclot and Platelet Mapping for Guiding Early Management of Severe COVID-19 Coagulopathy.
Laubscher GJ, Lourens PJ, Venter C, Kell DB, et al · · 2021 · cited 38× · PMID 34830660 · DOI 10.3390/jcm10225381 -
Descriptions of Scientific Evidence and Uncertainty of Unproven COVID-19 Therapies in US News: Content Analysis Study.
Watson S, Benning TJ, Marcon AR, Zhu X, et al · · 2024 · cited 1× · PMID 39207825 · DOI 10.2196/51328 -
Lipid metabolism, viral infection, and antiviral immunity: a new host-pathogen interface.
Yang LJ, Tang M, Yang L. · · 2026 · PMID 41868152 · DOI 10.3389/fcimb.2026.1765502 -
Early management of severe COVID-19 coagulopathy should be guided by TEG<sup>®</sup>, microclot and platelet mapping
Laubscher GJ, Lourens PJ, Venter C, Kell DB, et al · · 2021 · DOI 10.1101/2021.07.05.21260012
Verify or expand the search:
- PubMed search for NCT04714515
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Montelukast
Trials testing the same drug.
- NCT07320625 — Efficacy of Montelukast on STEMl Patients · Phase 3 · recruiting
- NCT07101445 — Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injecti · Phase 4 · recruiting
- NCT06356571 — A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Partici · Phase 2 · recruiting
- NCT05922761 — BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) · Phase 2 · recruiting
- NCT05896228 — Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma · Phase 2 · recruiting
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other University of Sargodha trials
Trials by the same sponsor.
- NCT05389943 — The Effect of Vitamin D3 Therapy in Post Menopausal Women and Assessment of Changes in Bone Mineral Density After Orally · Phase 1 · unknown
- NCT04810117 — Monitoring the IgG/IgM Antibodies in COVID-19 Patients · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04714515 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Sargodha
- Last refreshed: 19 January 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04714515.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing